The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIb study.
 
Lijuan Chen
Employment - Chengdu Zenitar Biomedical Technology Co., Ltd
Leadership - Chengdu Zenitar Biomedical Technology Co., Ltd
Stock and Other Ownership Interests - Chengdu Zenitar Biomedical Technology Co., Ltd
Honoraria - Chengdu Zenitar Biomedical Technology Co., Ltd
Research Funding - Chengdu Zenitar Biomedical Technology Co., Ltd
Patents, Royalties, Other Intellectual Property - Chengdu Zenitar Biomedical Technology Co., Ltd
Travel, Accommodations, Expenses - Chengdu Zenitar Biomedical Technology Co., Ltd
 
Linyu Yang
No Relationships to Disclose
 
Jie Wang
No Relationships to Disclose
 
Rui Liang
Employment - Chengdu Zenitar Biomedical Technology Co., Ltd
Honoraria - Chengdu Zenitar Biomedical Technology Co., LtdChengdu Zenitar Biomedical Technology Co., Ltd
Travel, Accommodations, Expenses - Chengdu Zenitar Biomedical Technology Co., Ltd
 
He Li
No Relationships to Disclose
 
Ke Tan
Employment - Chengdu Zenitar Biomedical Technology Co., Ltd
Honoraria - Chengdu Zenitar Biomedical Technology Co., Ltd
Travel, Accommodations, Expenses - Chengdu Zenitar Biomedical Technology Co., Ltd
 
Li Wang
No Relationships to Disclose
 
Ting Niu
No Relationships to Disclose
 
Weili Zhao
No Relationships to Disclose